Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials

The Pink Sheet takes a closer look at recent clinical announcements showing how rare disease therapy sponsors are already increasingly reliant on natural history studies to guide drug development.

vr-crowd
Increasing familiarity with the possibilities and constraints of natural history data can only help industry and regulators alike.

More from Approval Standards

More from Pathways & Standards